A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Latest Information Update: 12 Jan 2023
At a glance
- Drugs Cenplacel L (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 06 Jan 2023 Results from the re-analysis of long term follow-up data from three legacy Phase 1, Phase 1b/2a and Phase 1b studies of Cenplacel-L presented in a Celularity Media Release.
- 27 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jan 2015 Time frame of primary endpoint changed from 2 years to 1 year as reported by ClinicalTrials.gov record.